Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument.

Reaney, Matthew; Allen, Veleka; Sehnert, Amy J; Fang, Liang; Hagège, Albert A; Naidu, Srihari S; Olivotto, Iacopo

Reaney, Matthew; Allen, Veleka; Sehnert, Amy J; Fang, Liang; Hagège, Albert A; Naidu, Srihari S; Olivotto, Iacopo.

Afiliación

Reaney M; IQVIA, 3 Forbury Place, 23 Forbury Road, Reading, RG1 3JH, UK. matthew.reaney@iqvia.com.
Allen V; IQVIA, New York, NY, USA.
Sehnert AJ; MyoKardia, Inc. (a wholly owned subsidiary of Bristol Myers Squibb), Brisbane, CA, USA.
Fang L; MyoKardia, Inc. (a wholly owned subsidiary of Bristol Myers Squibb), Brisbane, CA, USA.
Hagège AA; Cardiology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Naidu SS; Westchester Medical Center, WMC Health Network, New York Medical College, Valhalla, NY, USA.
Olivotto I; Cardiomyopathy Unit, Careggi University Hospital, University of Florence, Florence, Italy.

Pharmacoecon Open ; 6(4): 563-574, 2022 Jul.

Article en En | MEDLINE | ID: mdl-35653062

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Pharmacoecon Open Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google